$ABBV News FDA approving drugs faster, and it ma
Post# of 94279
Posted On: 11/19/2013 7:04:40 PM
$ABBV News
FDA approving drugs faster, and it may stay that way, report says 6:10 p.m. Nov. 18, 2013 - Russ Britt
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Mixed bag of earnings ends up badly for two health-care firms 10:22 a.m. Oct. 25, 2013 - Russ Britt
Microsoft, Amazon, Zynga are stocks to watch 4:31 a.m. Oct. 25, 2013 - Sue Chang
FDA recommends new limits on pain drugs 10:25 p.m. Oct. 24, 2013 - Thomas M. Burton
Abbott Labs sets a brisk earnings pace by beating income forecasts 10:43 a.m. Oct. 16, 2013 - Russ Britt
AbbVie net falls 16% on separation costs 8:58 a.m. July 26, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 4:46 p.m. July 25, 2013 - blogs.marketwatch.com
The Next 24: Starbucks Surges 4:13 p.m. July 25, 2013 - MarketWatch
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 10:09 a.m. July 10, 2013 - Russ Britt
European regulators set precedent with approval of new copycat drugs 2:04 p.m. June 28, 2013 - Russ Britt
No rest for the weary, or even the savvy, in Wall Street carnage 4:21 p.m. June 20, 2013 - Russ Britt
Supreme Court satisfies few with ruling on generic drug settlements 4:30 p.m. June 18, 2013 - Russ Britt
Dan Loeb's cheap stock picks 11:39 a.m. June 18, 2013 - Insider Monkey
Pacts that delay sale of generics in jeopardy 1:55 a.m. June 18, 2013 - Brent Kendall
Supreme Court decision on generics hits Actavis, but few other drug firms 11:46 a.m. June 17, 2013 - Russ Britt
Abbott unveils $3 billion share-buyback program 2:22 p.m. June 14, 2013 - MarketWatch.com
Quant King Renaissance Technologies' stock picks 1:37 p.m. June 7, 2013 - Insider Monkey
Insiders and Dan Loeb like these stocks 11:00 a.m. June 4, 2013 - Insider Monkey
Newscast: First Solar shines after the bell 5:54 p.m. May 6, 2013 - MarketWatch
European Approval for Gilead's Vitekta - Analyst Blog 11:40 a.m. Today - Zacks.com
Celgene's Revlimid: Sales To $8B? Patent To 2023? 11:02 a.m. Today - Seeking Alpha
6 Value Dividend Stocks You Should Consider For Your Portfolio 9:43 a.m. Today - Seeking Alpha
AbbVie Hepatitis C Treatment Shines In Latest Trials 12:06 p.m. Nov. 18, 2013 - Investors Business Daily
AbbVie Hepatitis C Drug Shows Promise 10:04 a.m. Nov. 18, 2013 - WSJ.com
Tracking George Soros's Portfolio - Q3 2013 Update 5:54 a.m. Nov. 16, 2013 - Seeking Alpha
Corporate Watch 1:32 a.m. Nov. 14, 2013 - WSJ.com
FDA Approves Drug for Rare Blood Cancer 6:29 p.m. Nov. 13, 2013 - WSJ.com
Eli Lilly - A Short Position Seems Too Aggressive 10:28 a.m. Nov. 13, 2013 - Seeking Alpha
10-Q: ABBVIE INC. 5:00 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Stock Market News for November 12, 2013 - Market News 10:06 a.m. Nov. 12, 2013 - Zacks.com
The Street Can't Help but Love Amgen 6:00 a.m. Nov. 12, 2013 - TheStreet.com
Loss Narrows at Repros, Shares Down - Analyst Blog 11:50 a.m. Nov. 11, 2013 - Zacks.com
Does Bristol-Myers Squibb Deserve Overweight Rating? 7:57 a.m. Nov. 11, 2013 - Seeking Alpha
Pfizer And Merck Continue To Battle Declining Revenue 11:49 a.m. Nov. 10, 2013 - Seeking Alpha
4 Healthcare Sector Dogs Hype 13% To 17% October Upsides; 4% To 7.5% Downsides 7:02 p.m. Nov. 8, 2013 - Seeking Alpha
AbbVie's Not as Vulnerable as the Street Believes 6:30 a.m. Nov. 8, 2013 - TheStreet.com
Roche's Gazyva Approved in the U.S. - Analyst Blog 6:39 p.m. Nov. 7, 2013 - Zacks.com
Gilead Vs. Challengers In The Hepatitis C Race 7:00 a.m. Nov. 7, 2013 - Seeking Alpha
We Like What We're Seeing In Big Pharma 4:15 a.m. Nov. 5, 2013 - Seeking Alpha
Federal Legislation Support, Philanthropic Activities, and Patent Challenges - Research Report on Mylan, Abbott, Actavis, AbbVie, and Agilent Technologies 8:00 a.m. Today - PR Newswire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
AbbVie to Present at Jefferies 2013 Healthcare Conference 8:15 a.m. Nov. 14, 2013 - PR Newswire
Critical Alerts For Johnson and Johnson, AbbVie, Air Products and Chemicals, American Capital, and AFLAC Released By InvestorsObserver 9:31 a.m. Nov. 13, 2013 - PR Newswire
Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte 8:00 a.m. Nov. 8, 2013 - PR Newswire
AbbVie to Present at Credit Suisse 2013 Healthcare Conference 8:15 a.m. Nov. 7, 2013 - PR Newswire
Clinical Studies, Regulatory Clearance, Financial Results, and Approvals - Research Report on Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, AbbVie, and Novartis 9:00 a.m. Oct. 31, 2013 - PR Newswire
Positive Clinical Trial Results, Patient Enrollment, and Collaborations - Research Report on Pfizer, Medivation, AbbVie, Cigna, and AstraZeneca 9:00 a.m. Oct. 28, 2013 - PR Newswire
Pre-Market Analysis: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 10:12 a.m. Oct. 25, 2013 - PR Newswire
AbbVie Reports Third-Quarter 2013 Financial Results 7:54 a.m. Oct. 25, 2013 - PR Newswire
AbbVie Named a Science Top Employer 6:20 p.m. Oct. 24, 2013 - PR Newswire
Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and New Drug Applications - Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and Keryx 8:00 a.m. Oct. 18, 2013 - PR Newswire
OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies 9:00 a.m. Oct. 10, 2013 - BusinessWire
AbbVie to Host Third-Quarter Earnings Conference Call 8:01 a.m. Oct. 4, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 8:00 a.m. Oct. 4, 2013 - PR Newswire
AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease 6:00 a.m. Oct. 3, 2013 - PR Newswire
Drug Approvals, Trial Results, and Collaboration- Research Report on Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, AbbVie, and GSK 8:00 a.m. Sept. 30, 2013 - PR Newswire
Trace Insider Trading for Cisco, AbbVie, Comcast, Carnival, Intel, and Molycorp 8:55 a.m. Sept. 25, 2013 - PR Newswire
Dividends and Recognitions Affirming Strong Returns to Shareholders- Research Report on Merck, AbbVie, HealthSouth, Quintiles, and Ensign 8:00 a.m. Sept. 25, 2013 - PR Newswire
AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies 8:01 a.m. Sept. 24, 2013 - PR Newswire
FDA approving drugs faster, and it may stay that way, report says 6:10 p.m. Nov. 18, 2013 - Russ Britt
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Mixed bag of earnings ends up badly for two health-care firms 10:22 a.m. Oct. 25, 2013 - Russ Britt
Microsoft, Amazon, Zynga are stocks to watch 4:31 a.m. Oct. 25, 2013 - Sue Chang
FDA recommends new limits on pain drugs 10:25 p.m. Oct. 24, 2013 - Thomas M. Burton
Abbott Labs sets a brisk earnings pace by beating income forecasts 10:43 a.m. Oct. 16, 2013 - Russ Britt
AbbVie net falls 16% on separation costs 8:58 a.m. July 26, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 4:46 p.m. July 25, 2013 - blogs.marketwatch.com
The Next 24: Starbucks Surges 4:13 p.m. July 25, 2013 - MarketWatch
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 10:09 a.m. July 10, 2013 - Russ Britt
European regulators set precedent with approval of new copycat drugs 2:04 p.m. June 28, 2013 - Russ Britt
No rest for the weary, or even the savvy, in Wall Street carnage 4:21 p.m. June 20, 2013 - Russ Britt
Supreme Court satisfies few with ruling on generic drug settlements 4:30 p.m. June 18, 2013 - Russ Britt
Dan Loeb's cheap stock picks 11:39 a.m. June 18, 2013 - Insider Monkey
Pacts that delay sale of generics in jeopardy 1:55 a.m. June 18, 2013 - Brent Kendall
Supreme Court decision on generics hits Actavis, but few other drug firms 11:46 a.m. June 17, 2013 - Russ Britt
Abbott unveils $3 billion share-buyback program 2:22 p.m. June 14, 2013 - MarketWatch.com
Quant King Renaissance Technologies' stock picks 1:37 p.m. June 7, 2013 - Insider Monkey
Insiders and Dan Loeb like these stocks 11:00 a.m. June 4, 2013 - Insider Monkey
Newscast: First Solar shines after the bell 5:54 p.m. May 6, 2013 - MarketWatch
European Approval for Gilead's Vitekta - Analyst Blog 11:40 a.m. Today - Zacks.com
Celgene's Revlimid: Sales To $8B? Patent To 2023? 11:02 a.m. Today - Seeking Alpha
6 Value Dividend Stocks You Should Consider For Your Portfolio 9:43 a.m. Today - Seeking Alpha
AbbVie Hepatitis C Treatment Shines In Latest Trials 12:06 p.m. Nov. 18, 2013 - Investors Business Daily
AbbVie Hepatitis C Drug Shows Promise 10:04 a.m. Nov. 18, 2013 - WSJ.com
Tracking George Soros's Portfolio - Q3 2013 Update 5:54 a.m. Nov. 16, 2013 - Seeking Alpha
Corporate Watch 1:32 a.m. Nov. 14, 2013 - WSJ.com
FDA Approves Drug for Rare Blood Cancer 6:29 p.m. Nov. 13, 2013 - WSJ.com
Eli Lilly - A Short Position Seems Too Aggressive 10:28 a.m. Nov. 13, 2013 - Seeking Alpha
10-Q: ABBVIE INC. 5:00 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Stock Market News for November 12, 2013 - Market News 10:06 a.m. Nov. 12, 2013 - Zacks.com
The Street Can't Help but Love Amgen 6:00 a.m. Nov. 12, 2013 - TheStreet.com
Loss Narrows at Repros, Shares Down - Analyst Blog 11:50 a.m. Nov. 11, 2013 - Zacks.com
Does Bristol-Myers Squibb Deserve Overweight Rating? 7:57 a.m. Nov. 11, 2013 - Seeking Alpha
Pfizer And Merck Continue To Battle Declining Revenue 11:49 a.m. Nov. 10, 2013 - Seeking Alpha
4 Healthcare Sector Dogs Hype 13% To 17% October Upsides; 4% To 7.5% Downsides 7:02 p.m. Nov. 8, 2013 - Seeking Alpha
AbbVie's Not as Vulnerable as the Street Believes 6:30 a.m. Nov. 8, 2013 - TheStreet.com
Roche's Gazyva Approved in the U.S. - Analyst Blog 6:39 p.m. Nov. 7, 2013 - Zacks.com
Gilead Vs. Challengers In The Hepatitis C Race 7:00 a.m. Nov. 7, 2013 - Seeking Alpha
We Like What We're Seeing In Big Pharma 4:15 a.m. Nov. 5, 2013 - Seeking Alpha
Federal Legislation Support, Philanthropic Activities, and Patent Challenges - Research Report on Mylan, Abbott, Actavis, AbbVie, and Agilent Technologies 8:00 a.m. Today - PR Newswire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
AbbVie to Present at Jefferies 2013 Healthcare Conference 8:15 a.m. Nov. 14, 2013 - PR Newswire
Critical Alerts For Johnson and Johnson, AbbVie, Air Products and Chemicals, American Capital, and AFLAC Released By InvestorsObserver 9:31 a.m. Nov. 13, 2013 - PR Newswire
Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte 8:00 a.m. Nov. 8, 2013 - PR Newswire
AbbVie to Present at Credit Suisse 2013 Healthcare Conference 8:15 a.m. Nov. 7, 2013 - PR Newswire
Clinical Studies, Regulatory Clearance, Financial Results, and Approvals - Research Report on Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, AbbVie, and Novartis 9:00 a.m. Oct. 31, 2013 - PR Newswire
Positive Clinical Trial Results, Patient Enrollment, and Collaborations - Research Report on Pfizer, Medivation, AbbVie, Cigna, and AstraZeneca 9:00 a.m. Oct. 28, 2013 - PR Newswire
Pre-Market Analysis: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 10:12 a.m. Oct. 25, 2013 - PR Newswire
AbbVie Reports Third-Quarter 2013 Financial Results 7:54 a.m. Oct. 25, 2013 - PR Newswire
AbbVie Named a Science Top Employer 6:20 p.m. Oct. 24, 2013 - PR Newswire
Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and New Drug Applications - Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and Keryx 8:00 a.m. Oct. 18, 2013 - PR Newswire
OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies 9:00 a.m. Oct. 10, 2013 - BusinessWire
AbbVie to Host Third-Quarter Earnings Conference Call 8:01 a.m. Oct. 4, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 8:00 a.m. Oct. 4, 2013 - PR Newswire
AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease 6:00 a.m. Oct. 3, 2013 - PR Newswire
Drug Approvals, Trial Results, and Collaboration- Research Report on Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, AbbVie, and GSK 8:00 a.m. Sept. 30, 2013 - PR Newswire
Trace Insider Trading for Cisco, AbbVie, Comcast, Carnival, Intel, and Molycorp 8:55 a.m. Sept. 25, 2013 - PR Newswire
Dividends and Recognitions Affirming Strong Returns to Shareholders- Research Report on Merck, AbbVie, HealthSouth, Quintiles, and Ensign 8:00 a.m. Sept. 25, 2013 - PR Newswire
AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies 8:01 a.m. Sept. 24, 2013 - PR Newswire
(0)
(0)